Oral EPI 7386 Trial TT

The Efficacy and Resistance-Breaking Potential of EPI-7386 Masofaniten in Castration-Resistant Prostate Cancer - Andrew Laccetti

Details
Zach Klaassen engages Andrew Laccetti in a discussion about Masofaniten (EPI-7386), a pioneering anti-androgen therapy targeting the N-terminal domain of the androgen receptor, aimed at overcoming resistance mechanisms observed with current prostate cancer treatments. Detailing the progression from preclinical data to clinical trials, Dr. Laccetti highlights Masofaniten's potential synergy with en...

Dual Action Hormone Therapy Targeting Two Parts of Androgen Receptor Shows Tolerability and Early Efficacy for EPI-7386 (masofaniten) - Andrew Laccetti

Details
Rana McKay hosts Andrew Laccetti to discuss advancements in metastatic castration-resistant prostate cancer (mCRPC) treatments. Dr. Laccetti highlights the Phase I/II trial of masofaniten combined with enzalutamide, a novel hormonal therapy for mCRPC. Masofaniten, a first-in-class N-terminal ligand antagonist for the androgen receptor, shows promise in overcoming resistance to current hormonal the...

Attacking Androgen Receptor From Two Sides: The Potential of a Novel Drug Duo in Prostate Cancer - Christos Kyriakopoulos

Details
Alicia Morgans interviews Christos Kyriakopoulos about a study presented at ESMO on EPI-7386, also known as masofaniten. Dr. Kyriakopoulos elaborates on this phase one-two study, which explores the combination of EPI-7386 with enzalutamide in patients with metastatic castration-resistant prostate cancer. EPI-7386 is novel in targeting the androgen receptor's N-terminal domain, differing from other...

Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone

Details
Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors, u...

Masofaniten in Advanced Prostate Cancer: A Phase II Trial and Promising Insights - Mark Markowski

Details
Medical Oncologists Alicia Morgans and Mark Markowski discuss challenges in treating advanced prostate cancer, related to the evolving resistance requiring novel mechanisms of action to give us new options for treatment. A new drug, masofaniten (formerly EPI-7386), is being studied in a phase II trial for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to enroll 120 patient...

Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer- Andrew Laccetti

Details
Alicia Morgans is joined by Andrew Laccetti to discuss data on the combination of enzalutamide with the next-generation antigen EPI-7386 in chemotherapy-exposed patients with castration resistance in prostate cancer (CRPC) prior to exposure to any androgen receptor (AR) pathway inhibitor. EPI-7386 represents a new approach to disrupting the androgen receptor signaling pathway, the primary driver o...

Oral EPI-7386 Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Russell Pachynski

Details
Alicia Morgans is joined by Russell Pachynski to discuss EPI-7386, a first-in-class N-terminal domain androgen receptor (AR) inhibitor that suppresses androgen activity through a novel mechanism of action. Trial of this agent in a first-in-human study in heavily pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Pachynski provides an overview of this section of...